AG
ABERCROMBIE GEORGE B
Directeur
OtherM
Insider track record
ExecutiveAcross 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the detailed record of transactions filed by ABERCROMBIE GEORGE B, Directeur. Director active across 2 companies, notably Biocryst Pharmaceuticals INC. Aggregated, 18 filings have been recorded. Breakdown: 0 buy · 2 sells. Total volume traded: €146k. Activity tracked since 10 May 2021. The latest transaction was filed on 12 June 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations18 total
6,820 shares0Common StockSEC:0001127602-24-018705:0
16,745 shares0Common StockSEC:0001127602-23-018765:0
12,866 shares0Common StockSEC:0001127602-22-017153:0
5,000 shares@ US$3.320.0009% mcap5.0% of flowCommon StockSEC:0001127602-22-012272:0
5,000 shares@ US$3.320.0009% mcap4.7% of flowCommon StockSEC:0001127602-22-005295:0
5,000 shares@ US$3.320.0009% mcap4.7% of flowCommon StockSEC:0001127602-21-029440:0
5,000 shares@ US$3.320.0009% mcap10.3% of flowCommon StockSEC:0001127602-21-029440
5,000 shares@ US$2.630.0007% mcap3.6% of flowCommon StockSEC:0001127602-21-025496:0
5,000 shares@ US$2.633.6% of flowCommon StockSEC:0001127602-21-025496
11,000 shares@ US$1.710.0010% mcap5.1% of flowCommon StockSEC:0001127602-21-025252:0
11,000 shares@ US$1.715.1% of flowCommon StockSEC:0001127602-21-025252
5,000 shares@ US$2.633.6% of flowCommon StockSEC:0001127602-21-022226
5,000 shares@ US$2.630.0007% mcap3.6% of flowCommon StockSEC:0001127602-21-022226:0
6,667 shares@ US$2.630.0009% mcap4.6% of flowCommon StockSEC:0001127602-21-018061:0
6,667 shares@ US$2.634.6% of flowCommon StockSEC:0001127602-21-018061
7,000 shares@ US$12.7023.6% of flowCommon StockSEC:0001127602-21-016433
7,000 shares@ US$12.700.0044% mcap23.6% of flowCommon StockSEC:0001127602-21-016433:0
92,587 sharesCommon StockSEC:0001179110-16-017814:0
About ABERCROMBIE GEORGE B
George B. Abercrombie is a Director at BIOCRYST PHARMACEUTICALS INC. In this role, he contributes to the governance of the company and the development of strategies aimed at improving performance. His experience in the pharmaceutical sector allows him to provide valuable insights on innovation and research. He is committed to supporting the company's growth initiatives.